Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) reported strong Q2 2025 results, exceeding guidance with net sales of $534 million, representing a 7% increase at actual rates and 6% at constant exchange rates (CER). The company achieved an adjusted operating income margin of 29.9%, up 1.5 percentage points from Q2 2024, and delivered adjusted diluted EPS of $0.60.

Key growth drivers included QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER), contributing to an 11% CER growth in diagnostic solutions. Based on strong H1 2025 performance, QIAGEN increased its FY 2025 outlook to 4-5% CER net sales growth and reaffirmed its adjusted diluted EPS target of $2.35 CER. The company has returned over $350 million to shareholders in 2025 through a synthetic share repurchase and its first-ever cash dividend.

QIAGEN (NYSE: QGEN) has launched QIAseq xHYB Long Read Panels, a new suite of target enrichment solutions designed for long-read sequencing of complex genomic regions. The panels are optimized for native long-read platforms, including PacBio's technology, and aim to improve analysis of structural variants, HLA typing, and repeat expansions.

Built on QIAGEN's hybrid-capture chemistry, the panels offer high target completeness, flexible formats including fixed panels for hereditary cancers and HLA typing, compatibility with high-molecular-weight DNA extraction kits, and integration with QIAGEN Digital Insights bioinformatics. The launch strengthens QIAGEN's position in providing solutions for both short- and long-read NGS technologies.

QIAGEN (NYSE: QGEN) has scheduled its Q2 2025 earnings release and conference call. The company will release its second quarter results on Tuesday, August 5, 2025, after market close at 22:05 Frankfurt time (21:05 London/16:05 New York).

The earnings conference call will be held the following day, Wednesday, August 6, at 15:30 Frankfurt time (14:30 London/09:30 New York). Participants can join through multiple channels including call-back registration, direct dial-in, or audio webcast. A replay of the conference call will be made available afterward.

QIAGEN (NYSE: QGEN) announced significant leadership changes and shareholder-friendly initiatives. Stephen H. Rusckowski, former Chairman, President and CEO of Quest Diagnostics, has been elected as Chairman of the Supervisory Board, succeeding Lawrence A. Rosen who stepped down after 12 years of service.

At the Annual General Meeting (AGM), with 80.4% shareholder representation, all proposed resolutions were approved, including two major financial initiatives: the company's first-ever annual cash dividend of $0.25 per share (approximately $54 million total) and a new synthetic share repurchase authorization of up to $500 million.

Following the AGM, QIAGEN's Supervisory Board now consists of eight members, implementing a planned reduction to historical levels while maintaining necessary expertise for the company's future development.

QIAGEN (NYSE: QGEN) has announced a strategic partnership with GENCURIX to develop oncology assays for the QIAcuityDx digital PCR platform. As the inaugural partner in QIAGEN's new QIAcuityDx Partnering Program, GENCURIX will develop multiplex oncology assays for tissue and liquid biopsies. The partnership leverages QIAGEN's QIAcuityDx platform, which has achieved over 2,700 cumulative placements by end of 2024, and GENCURIX's expertise in multiplex assay development. The collaboration aims to expand the menu of in vitro diagnostic (IVD) assays, with GENCURIX responsible for regulatory approvals while QIAGEN will handle global marketing through its commercial infrastructure. This partnership represents a significant step in increasing access to digital PCR diagnostics and complementing existing methods like qPCR and NGS.

QIAGEN (QGEN) and Incyte (INCY) have announced a global collaboration to develop a novel diagnostic panel for myeloproliferative neoplasms (MPNs). The partnership focuses on creating a multimodal panel using next-generation sequencing technology to detect gene alterations in blood cancers, particularly targeting mutant calreticulin (mutCALR). The panel will support Incyte's drug portfolio, including INCA033989, and will be validated on Illumina's NextSeq 550Dx platform. QIAGEN will handle regulatory submissions and market access across the US, EU, and Asia-Pacific regions. The collaboration aims to improve treatment decisions for MPN patients, which represent about 40% of hematological malignancies, by enabling precise identification of genomic aberrations in biomarkers like CALR.

Tracer Biotechnologies and QIAGEN (NYSE: QGEN) have announced a strategic partnership to develop and commercialize minimal residual disease (MRD) testing solutions for solid tumors using QIAGEN's QIAcuity digital PCR platform. The collaboration aims to create sensitive, cost-effective, and decentralized blood-based MRD tests to monitor cancer recurrence and guide treatment decisions. Tracer offers two MRD solutions: Tracer dPCR for tumor-informed testing and Tracer WGS, an AI-powered whole-genome ctDNA platform for tumor-agnostic detection. This partnership strengthens QIAGEN's position in oncology and expands their companion diagnostic capabilities, while advancing Tracer's mission to democratize MRD testing across institutions.

QIAGEN (NYSE: QGEN) has announced two strategic partnerships to expand its minimal residual disease (MRD) testing capabilities in oncology. The company partnered with Tracer Biotechnologies to develop blood-based MRD tests for solid tumors using QIAcuity digital PCR systems, and with Foresight Diagnostics to create a kit version of its CLARITY™ NGS assay for lymphoma. These partnerships aim to advance decentralized, non-invasive tools for cancer monitoring and personalized treatment decisions. The collaborations will support pharmaceutical companies' clinical trials and companion diagnostic development. QIAGEN's comprehensive MRD portfolio includes sample technologies, testing platforms, and digital insights solutions, with plans to launch an upgraded QIAsymphony Connect version in late 2025.

Foresight Diagnostics and QIAGEN (NYSE: QGEN) have announced a strategic worldwide partnership to develop and commercialize a kit version of Foresight's CLARITY™ assay for minimal residual disease (MRD) detection in lymphoma and other blood cancers. The collaboration combines Foresight's MRD detection technology with QIAGEN's global molecular diagnostic expertise. The partnership aims to create a standardized, regulated diagnostic kit that would be unique in offering both central laboratory service and diagnostic capabilities for ctDNA-based MRD testing. This kit, once validated and approved, will support clinical decision-making and therapeutic strategies for hematological cancer patients, enabling personalized treatment approaches through next-generation sequencing technology.